Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Raptiva Labeling Should Require Monitoring For Thrombocytopenia – Cmte.

Executive Summary

Genentech/Xoma Raptiva labeling should require platelet count monitoring to minimize the risk of thrombocytopenia, FDA Dermatologic & Ophthalmic Drugs Advisory Committee recommended

You may also be interested in...



Genentech Raptiva To Undergo 5,000-Patient Postmarketing Safety Study

Genentech will conduct a 5,000-patient study of the incidence of adverse events associated with Raptiva (efalizumab) as a condition of FDA approval of the psoriasis treatment

Genentech Raptiva To Undergo 5,000-Patient Postmarketing Safety Study

Genentech will conduct a 5,000-patient study of the incidence of adverse events associated with Raptiva (efalizumab) as a condition of FDA approval of the psoriasis treatment

Genentech/Xoma Raptiva Clears FDA, Priced At 25% Discount to Amevive

Genentech/Xoma's psoriasis therapy Raptiva will be available by Thanksgiving at a 25% discount to a full year of Biogen's intramuscular injection formulation of Amevive

Related Content

UsernamePublicRestriction

Register

LL009864

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel